Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 panorama 1 study

This article has no abstract
Epistemonikos ID: 42218d0bd8e0fde69bf3c020b3d94b096cc387f5
First added on: Feb 06, 2025